Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Contineum Therapeutics, Inc. - Common stock
(NQ:
CTNM
)
15.76
+0.27 (+1.74%)
Streaming Delayed Price
Updated: 10:33 AM EDT, Aug 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
82,820
Open
15.22
Bid (Size)
15.70 (200)
Ask (Size)
15.87 (200)
Prev. Close
15.49
Today's Range
15.19 - 16.07
52wk Range
5.710 - 16.91
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
July 30, 2026
From
Contineum Therapeutics, Inc.
Via
Business Wire
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
June 30, 2026
From
Contineum Therapeutics, Inc.
Via
Business Wire
Performance
YTD
+38.4%
+38.4%
1 Month
+1.5%
+1.5%
3 Month
+11.4%
+11.4%
6 Month
+9.6%
+9.6%
1 Year
+171.7%
+171.7%
More News
Read More
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
June 01, 2026
From
Contineum Therapeutics, Inc.
Via
Business Wire
Contineum Therapeutics (NASDAQ:CTNM) Reports Q4 2025 Loss, Highlights Clinical Progress and Extended Cash Runway
↗
March 05, 2026
Via
Chartmill
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential
↗
May 22, 2026
Via
MarketBeat
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2026
From
Contineum Therapeutics, Inc.
Via
Business Wire
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
May 12, 2026
From
Contineum Therapeutics, Inc.
Via
Business Wire
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
May 11, 2026
From
Contineum Therapeutics, Inc.
Via
Business Wire
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
May 05, 2026
From
Contineum Therapeutics, Inc.
Via
Business Wire
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2026
From
Contineum Therapeutics, Inc.
Via
Business Wire
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
April 30, 2026
From
Contineum Therapeutics, Inc.
Via
Business Wire
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2026
From
Contineum Therapeutics, Inc.
Via
Business Wire
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
March 05, 2026
From
Contineum Therapeutics, Inc.
Via
Business Wire
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
March 03, 2026
From
Contineum Therapeutics, Inc.
Via
Business Wire
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 18, 2026
From
Contineum Therapeutics, Inc.
Via
Business Wire
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 28, 2026
From
Contineum Therapeutics, Inc.
Via
Business Wire
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
December 11, 2025
From
Contineum Therapeutics, Inc.
Via
Business Wire
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering
December 11, 2025
From
Contineum Therapeutics, Inc.
Via
Business Wire
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference
November 24, 2025
From
Contineum Therapeutics
Via
Business Wire
Get insights into the top gainers and losers of Thursday's after-hours session.
↗
November 20, 2025
Via
Chartmill
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
November 20, 2025
From
Contineum Therapeutics, Inc.
Via
Business Wire
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
October 30, 2025
From
Contineum Therapeutics, Inc.
Via
Business Wire
This Lululemon Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
↗
September 25, 2025
Via
Benzinga
This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
September 25, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
September 24, 2025
Via
Benzinga
Frequently Asked Questions
Is Contineum Therapeutics, Inc. - Common stock publicly traded?
Yes, Contineum Therapeutics, Inc. - Common stock is publicly traded.
What exchange does Contineum Therapeutics, Inc. - Common stock trade on?
Contineum Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Contineum Therapeutics, Inc. - Common stock?
The ticker symbol for Contineum Therapeutics, Inc. - Common stock is CTNM on the Nasdaq Stock Market
What is the current price of Contineum Therapeutics, Inc. - Common stock?
The current price of Contineum Therapeutics, Inc. - Common stock is 15.76
When was Contineum Therapeutics, Inc. - Common stock last traded?
The last trade of Contineum Therapeutics, Inc. - Common stock was at 08/03/26 10:33 AM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
